This paper, presented by Hwang et al., evaluates the treatment and management options of cytomegalovirus retinitis (CMVR). CMVR presents as an ocular infection that is often found in immunocompromised patients, specifically those with HIV and AIDS. The utilization of highly active antiretroviral therapy (HAART) brought vision impairment from CMVR from 30% to slightly under 5%. This paper reviews existing literature on CMVR to propose a general consensus among management plans for those with CMVR. The search was based on five broad categories: diagnostic controversies, screening controversies, treatment controversies, special population considerations, and emerging controversies. The general consensus with regards to screening controversies indicated that: clinical diagnosis emphasize patients that have a compromised immune function, other retinitis can be difficult to distinguish from CMVR, PCR testing for introocular fluid is the preferred method for confirmation of diagnosis, and more aggressive interventions should be considered for high risk patients. With regards to screening, the consensus was monthly screening should be advised for HIV patients with a low CD4+ T-cell (50 cells/uL) and more frequent screening for those in lower income households. With regards to treatment, the first treatment plan should be oral valganciclovir; maintenance of treatment and treatment plans can be reconsidered after 6 months; utilizing both second-line antiviral agents with first-line drugs should be considered; and a vitrectomy should be performed for patients who have a retinal detachment along with CVMR. With regards to future directions, the general consensus concluded that utilizing deep learning diagnostic systems can be extremely helpful in the future for identifying vision threatening CMVR cases, which can boost efficiency and improve patient outcomes.